One of the leading direct-to-consumer telehealth platforms just stamped its passport...again. The company closed its acquisition of an Australian digital health platform behind several well-known wellness brands. Stacked on top of two earlier European deals, this telehealth player now operates across the US, UK, Australia, Canada, France, Germany, Ireland, Spain, and Japan.
The Australian acquisition brings 850,000+ customers onto the platform as of May 2026 and runs north of $450 million in annual revenue. Those are incremental to the long-term targets management reaffirmed last quarter: at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, set before the Australian business is in the model.
What LikeFolio Data Says
Our consumer data paints an interesting setup. This name carries a LikeFolio Score of 74, supported by a Main Street Score of 66 — real consumer purchase intent is firmly positive. The themes powering that demand — GLP-1 & Weight Loss Economy, Longevity & Wellness, and Healthcare — are all flashing Very Bullish or Bullish in our system.
Wall Street hasn't caught up. The Wall Street Score sits at just 44, meaning the sell-side is still positioning cautiously even as the consumer signal accelerates. That gap between consumer reality and analyst modeling is the exact mispricing we hunt for across the telehealth and digital-health complex — and it's worth noting that several peers in the space (legacy virtual-care platforms, prescription-discount players, and ACA-focused insurers) are not seeing the same consumer momentum, which makes the divergence even more interesting.
Peptides Are the Hidden Catalyst
This is where it gets interesting. The company made a major move into peptides with the acquisition of a California-based peptide manufacturing facility, with the CEO calling peptide demand "future-facing innovation."
On April 15, the FDA scheduled a July 23–24 Pharmacy Compounding Advisory Committee meeting to weigh adding 7 restricted peptides back to the list licensed pharmacies can legally compound — among them MOTS-c (under review for obesity), BPC-157 (ulcerative colitis), and TB-500 (wound healing). It's a regulatory door cracking open right as the U.S. compounded weight-loss opportunity tightens, giving this platform a path to repurpose GLP-1 capacity into new revenue. Management plans to launch a longevity specialty in 2026 featuring peptides, coenzymes, and GLP/GIP treatments.
Bottom line
Consumer interest in peptides is exploding — search trends and social chatter line up directly with the longevity boom our themes are tracking. This company already owns the manufacturing footprint and the subscriber base to monetize it.
The just-closed Australian deal turns this name into a truly global consumer health platform with line-of-sight on Japan, Australia, and deeper European penetration. Layer in the FDA peptide review and a 2026 longevity specialty launch, and you have two distinct catalysts the Street still isn't modeling. Wall Street at 44 versus our LikeFolio Score of 74 — that's the dislocation.
Upgrade to see exactly which name we're playing — and at what level.